http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3641801-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fd8da0a02c7c4256f144f2c47dc0bab8 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-397 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21109 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6424 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-435 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-435 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-48 |
| filingDate | 2018-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed21944a3e90e4d4766a5aeffafe877f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20a1214096514bae1da9e85bb712ef4a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b0b329a0618ffbc18c0076ba20b3d82 |
| publicationDate | 2020-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3641801-A1 |
| titleOfInvention | Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use |
| abstract | The invention provides MTSP-1 polypeptides modified to have altered activity and / or specificity to cleave a complement protein, such as complement C3 protein, to inhibit its activity and thereby inhibit complement activation. Modified MTSP-1 polypeptides that inhibit complement activation can be used for the treatment of diseases and conditions in which complement activation plays a role. These diseases and conditions include inflammatory diseases and diseases with an inflammatory component. Examples of these disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, ophthalmic disorders, such as diabetic retinopathies. and macular degeneration, including age-related macular degeneration (AMD), and transplanted organ rejection, such as renal graft function failure (DGF). |
| priorityDate | 2017-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 898.